PSC
RVNC

Piper Sandler & Co’s Revance Therapeutics, Inc. RVNC Stock Holding History

Piper Sandler & Co’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,546
Closed -$30K – 166
2014
Q3 		$30K Buy
+1,546
New +$40.3K 0.02% 116

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Piper Sandler & Co's RVNC Position: Q4 2014 in Review

Piper Sandler & Co sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2014, closing a stake of 1,546 shares — an estimated $30K sold.

Piper Sandler & Co first reported a position in RVNC in Q3 2014 and held it in 1 quarter. The position peaked at $30K in Q3 2014. 69 funds tracked by Wall St. Rank hold RVNC as of Q4 2014.

  • Piper Sandler & Co reported no remaining Revance Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Piper Sandler & Co sold 1,546 Revance Therapeutics, Inc. shares in Q4 2014, an estimated $30K.
  • Piper Sandler & Co first reported a position in Revance Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • Piper Sandler & Co's Revance Therapeutics, Inc. position peaked at $30K in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2014.

Based on Piper Sandler & Co's 13F filing for Q4 2014, filed 17 Feb 2015.